Lipocine Inc
LPCN8.490USD
+0.770+9.97%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
46.02MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Lipocine Inc Unternehmen
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Lipocine Inc Informationen
BörsenkürzelLPCN
Name des UnternehmensLipocine Inc
IPO-datumMar 21, 2014
CEOPatel (Mahesh V)
Anzahl der mitarbeiter16
WertpapierartOrdinary Share
GeschäftsjahresendeMar 21
Addresse675 S Arapeen Dr Ste 202
StadtSALT LAKE CITY
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl84108-1295
Telefon18019947383
Websitehttps://www.lipocine.com/
BörsenkürzelLPCN
IPO-datumMar 21, 2014
CEOPatel (Mahesh V)
Führungskräfte von Lipocine Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
109.05K
+1630.00%
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
40.80K
--
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.41K
+456.00%
Ms. Krista Fogarty
Ms. Krista Fogarty
Principal Accounting Officer, Corporate Controller
Principal Accounting Officer, Corporate Controller
1.07K
+330.00%
Dr. Richard Dana Ono, Ph.D.
Dr. Richard Dana Ono, Ph.D.
Independent Director
Independent Director
831.00
--
Mr. Jeffrey A. (Jeff) Fink
Mr. Jeffrey A. (Jeff) Fink
Independent Director
Independent Director
386.00
--
Dr. Jill M. Jene, Ph.D.
Dr. Jill M. Jene, Ph.D.
Independent Director
Independent Director
--
--
Mr. Spyros Papapetropoulos, M.D., Ph.D.
Mr. Spyros Papapetropoulos, M.D., Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
109.05K
+1630.00%
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
40.80K
--
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.41K
+456.00%
Ms. Krista Fogarty
Ms. Krista Fogarty
Principal Accounting Officer, Corporate Controller
Principal Accounting Officer, Corporate Controller
1.07K
+330.00%
Dr. Richard Dana Ono, Ph.D.
Dr. Richard Dana Ono, Ph.D.
Independent Director
Independent Director
831.00
--
Mr. Jeffrey A. (Jeff) Fink
Mr. Jeffrey A. (Jeff) Fink
Independent Director
Independent Director
386.00
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sat, Dec 27
Aktualisiert: Sat, Dec 27
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Squadron Capital Management LLC
9.01%
The Vanguard Group, Inc.
4.00%
Patel (Mahesh V)
1.96%
BlackRock Institutional Trust Company, N.A.
1.61%
Geode Capital Management, L.L.C.
1.10%
Andere
82.33%
Aktionäre
Aktionäre
Anteil
Squadron Capital Management LLC
9.01%
The Vanguard Group, Inc.
4.00%
Patel (Mahesh V)
1.96%
BlackRock Institutional Trust Company, N.A.
1.61%
Geode Capital Management, L.L.C.
1.10%
Andere
82.33%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
15.84%
Individual Investor
2.84%
Investment Advisor/Hedge Fund
1.89%
Hedge Fund
0.93%
Andere
78.50%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
32
1.04M
18.66%
+478.43K
2025Q3
32
528.39K
9.52%
-40.19K
2025Q2
44
680.47K
12.56%
-41.55K
2025Q1
65
678.55K
12.68%
-110.89K
2024Q4
72
645.33K
12.07%
-219.30K
2024Q3
75
703.77K
13.16%
-136.61K
2024Q2
79
690.86K
12.92%
-132.01K
2024Q1
82
639.82K
12.02%
-214.82K
2023Q4
86
649.80K
12.29%
-222.39K
2023Q3
91
667.07K
12.61%
-176.35K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Squadron Capital Management LLC
500.00K
9.01%
+500.00K
--
Dec 18, 2025
The Vanguard Group, Inc.
221.87K
4%
-3.01K
-1.34%
Sep 30, 2025
Patel (Mahesh V)
109.05K
1.96%
+1.63K
+1.52%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
89.27K
1.61%
--
--
Sep 30, 2025
Geode Capital Management, L.L.C.
61.08K
1.1%
--
--
Sep 30, 2025
Susquehanna International Group, LLP
46.76K
0.84%
+742.00
+1.61%
Sep 30, 2025
Higuchi (John W)
40.80K
0.73%
--
--
Mar 31, 2025
Renaissance Technologies LLC
36.10K
0.65%
+1.30K
+3.74%
Sep 30, 2025
State Street Investment Management (US)
18.63K
0.34%
--
--
Sep 30, 2025
Citadel Advisors LLC
14.25K
0.26%
+14.25K
--
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%
DFA Dimensional US Sustainability Core 1 ETF
Anteil0%
Dimensional US Core Equity 1 ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
Datum
Ex-Dividendentag
Art
Verhältnis
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
